Skip to main content
0151 350 1590
Back to news

World Clinical Trials Day signals rebrand for leading Cheshire healthcare business

EMS Healthcare, the UK’s largest mobile clinical research partner, today unveiled a new look, courtesy of a refreshed visual identity and new website designed to reflect the company’s ambitions.

Keith Austin Keith Austin

Published 18 May 2023

World Clinical Trials Day signals rebrand for leading Cheshire healthcare business Press release

The brand launch comes in a week which culminates with World Clinical Trials Day on Saturday (May 20th). It’s a key moment in the healthcare calendar and this year has a particular resonance, with a government review into clinical trials currently underway.

Keith Austin, EMS Healthcare’s CEO, said: “Our vibrant new branding reflects the way our business is continuing to successfully evolve. Our heritage lies in supporting NHS Trusts with additional capacity, but we recognise there is now also significant pressure on the UK’s ability to deliver clinical trials, especially in hard-to-reach communities.” 

The NHS-Galleri trial - a revolutionary new blood test which can detect more than 50 types of cancer - has been using EMS Healthcare mobile units stationed in retail car parks and other convenient community locations across the UK. The trial reached its target of 140,000 people within 10 months and achieved a participant satisfaction rating of 97%. 

An independent review of clinical trials by Lord James O’Shaughnessy, was set up by the government in February and EMS Healthcare submitted a formal response last month.  

Keith Austin added: “In our submission to the O’Shaughnessy review, we emphasised that with the NHS continuing to face extreme capacity pressures, ongoing innovation will be critical to maintaining research momentum. The decentralisation of clinical trials and major research programmes such as Our Future Health, must continue at pace, if we are to deliver on our future ambitions for transforming health outcomes.”

The O’Shaughnessy review is expected to publish its findings in the next few weeks.